Abstract
Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Volume: 11 Issue: 2
Author(s): Alessandra Puddu and Giorgio L. Viviani
Affiliation:
Keywords: Diabetes, advanced glycation end products, pancreatic β-cells, insulin resistance, metabolic syndrome, hyperglycemia, glucose homeostasis, methylglyoxal, glycolaldehyde, AGE pentosidine, phosphorylation, musculoskeletal tissues
Abstract: Advanced Glycation Endproducts (AGEs) are a group of heterogeneous compounds formed by the non enzymatic reactions between aldehydic group of reducing sugars with proteins, lipids or nucleic acids. Formation and accumulation of AGEs are related with the aging process and are accelerated in diabetes. Type 2 diabetes are the most common form of diabetes, which are characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta cell function and mass. The pathogenic role of AGEs in vascular diabetic complications is widely recognised. Recently, other aspects of the detrimental effects of AGEs in type 2 diabetes have emerged: AGEs interfere with the complex molecular pathway of insulin signalling, leading to insulin resistance; AGEs modify the insulin molecule, and consequently, its function; AGEs decrease insulin secretion and insulin content. In this article, we review the role of AGEs in type 2 diabetes, beyond their involvement in vascular complications.
Export Options
About this article
Cite this article as:
Puddu Alessandra and L. Viviani Giorgio, Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564115
DOI https://dx.doi.org/10.2174/187153011795564115 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Antioxidant and Antiinflammatory Activities of Curcumin on Diabetes Mellitus and its Complications
Current Pharmaceutical Design Vitamin C: Basic Metabolism and Its Function as an Index of Oxidative Stress
Current Medicinal Chemistry Investigation of Chemical Compounds, Antioxidant and Antimicrobial Properties of Teucrium arduini L. (Lamiaceae)
Current Drug Targets A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews Editorial (Thematic Issue: Advances in the Pharmacokinetics of Natural Bioactive Polyphenols)
Current Drug Metabolism Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Point-of-Care Testing in Diabetes Care
Mini-Reviews in Medicinal Chemistry Cannabinoids
Current Drug Targets - CNS & Neurological Disorders The Future of Continuous Glucose Monitoring: Closed Loop
Current Diabetes Reviews Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir
Current Diabetes Reviews Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Pulmonary Complications in Diabetes Mellitus: The Role of Glycemic Control
Current Drug Targets - Inflammation & Allergy PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design